Semax vs Selank: Nootropic and Anxiolytic Research Compared

Research-only note: This article is for educational purposes and discusses compounds intended strictly for in vitro and laboratory research. The information below is not medical advice, and the products referenced are not for human consumption.

Semax vs Selank is a comparison of two synthetic heptapeptides built on the same design principle from two completely different parent molecules. Both attach a stabilising Pro-Gly-Pro tail to a short biologically active fragment, and both are studied as regulatory peptides in neuroscience research. What separates them is lineage: Semax derives from the ACTH(4-10) melanocortin fragment and is studied for neurotrophic signalling, while Selank derives from the immunopeptide tuftsin and is studied for GABAergic and neuroimmune endpoints.

Key takeaways

  • Semax vs Selank contrasts a melanocortin-lineage peptide with a tuftsin-lineage one.
  • Both are seven amino acids long and both use a C-terminal Pro-Gly-Pro tail for protease resistance.
  • Semax is Met-Glu-His-Phe-Pro-Gly-Pro, built on the ACTH(4-7) fragment.
  • Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, built on the tuftsin tetrapeptide.
  • Research on Semax centres on BDNF, NGF and TrkB signalling; research on Selank centres on GABAergic and neuroimmune pathways.
  • Neither carries the hormonal activity of its parent molecule, which is the point of the modification.
  • Both are lyophilized, third-party tested, and supplied for in vitro research only.

What the Semax vs Selank comparison is about

Regulatory peptides are short sequences that modulate signalling systems rather than acting as classical single-target agonists. The practical problem with using them experimentally is that short peptides are cleaved rapidly. Russian peptide chemistry solved this in both cases the same way, by appending Pro-Gly-Pro, a tripeptide that markedly slows enzymatic degradation while leaving the active fragment intact.

So the Semax vs Selank question is not about which stabilisation strategy is better — they share one. It is about which biological system the stabilised fragment engages.

  • Shared design: a short active fragment plus a C-terminal Pro-Gly-Pro stabiliser.
  • Shared length: seven residues each.
  • Semax parent: adrenocorticotropic hormone, fragment 4-10.
  • Selank parent: tuftsin, a fragment of the immunoglobulin G heavy chain.
  • Removed liability: Semax lacks steroidogenic corticotropic action; Selank lacks the instability of native tuftsin.
  • Physical form: both supplied as white lyophilized powders requiring reconstitution.

Semax vs Selank: mechanism of action

The two peptides diverge sharply once past the shared architecture. Semax acts primarily on neurotrophic and monoaminergic systems. Selank acts on inhibitory neurotransmission and immune signalling. Neither engages a single receptor cleanly, which is characteristic of regulatory peptides generally: the observed effects are shifts in the balance of several systems rather than the saturation of one target.

  • Semax raises BDNF protein and TrkB phosphorylation in hippocampal tissue in rodent work.
  • Exon III BDNF and TrkB mRNA rise alongside the protein-level changes.
  • Semax also modulates monoaminergic tone, which is why attention and learning paradigms feature heavily.
  • Neuroprotective endpoints appear in cerebral ischaemia-reperfusion models.
  • Selank alters expression of genes governing GABAergic neurotransmission in cortical tissue and cell lines.
  • Its anxiolytic profile in animal models has been compared with benzodiazepine reference compounds.
  • Selank additionally shows enkephalinergic activity, slowing enkephalin degradation.
  • The tuftsin lineage brings neuroimmune readouts, including cytokine and interferon endpoints.

The neurotrophic arm is documented in work showing Semax regulates BDNF and TrkB expression in the rat hippocampus, and the inhibitory arm in work on Selank and the expression of genes involved in GABAergic neurotransmission.

Semax vs Selank compared

The table sets out the Semax vs Selank differences that matter when selecting a compound for a model.

Property Semax Selank
Sequence Met-Glu-His-Phe-Pro-Gly-Pro Thr-Lys-Pro-Arg-Pro-Gly-Pro
Parent molecule ACTH(4-10), a melanocortin fragment Tuftsin, an IgG-derived immunopeptide
Primary pathway BDNF / NGF and TrkB neurotrophic signalling GABAergic neurotransmission
Secondary pathways Monoaminergic tone, neuroprotection Enkephalinergic and neuroimmune signalling
Research emphasis Cognition, learning, ischaemic models Anxiety-related behaviour, immune crosstalk
Parent liability removed Corticotropic / steroidogenic activity Rapid enzymatic degradation

Why the Semax vs Selank differences matter in practice:

  • Neurotrophic and GABAergic readouts require different assays and different timescales.
  • A cognition paradigm will not detect an anxiolytic-type effect, and vice versa.
  • Selank’s immune activity makes immune status a variable in its models, not background.
  • Semax’s monoaminergic component overlaps with stimulant-adjacent paradigms and needs matching controls.
  • Shared Pro-Gly-Pro chemistry means shared handling, but not shared endpoints.

Semax vs Selank research applications

Published preclinical work on Semax vs Selank clusters into distinct, largely non-overlapping areas:

  • Learning and memory paradigms: acquisition and retention tasks in rodent models.
  • Neurotrophin signalling: BDNF, NGF and TrkB expression and phosphorylation.
  • Ischaemia models: protein-expression profiling after cerebral ischaemia-reperfusion.
  • Anxiety-related behaviour: elevated-plus-maze and comparable rodent paradigms.
  • GABAergic gene expression: transcript panels in cortical tissue and neuroblastoma lines.
  • Neuroimmune crosstalk: cytokine and interferon readouts tied to the tuftsin lineage.
  • Analytical work: HPLC and LC-MS confirmation of heptapeptide identity and purity.

Both compounds have an unusually long research history for peptides of this class, and much of it predates modern reporting standards, so study quality varies considerably. A clinical literature also exists for both, largely from Russian research groups, and it is referenced here only as scientific context. It does not alter the status of the material supplied on this site, which is a research reagent and nothing else.

Why Semax vs Selank is often studied as a pair

The two peptides are frequently discussed together because they came out of the same laboratory tradition and share a stabilisation motif, not because they are interchangeable. Studied side by side, they let a research design separate neurotrophic effects from inhibitory-neurotransmission effects using compounds matched for length, chemistry and handling.

  • Matched size and stability remove two confounds from a two-arm comparison.
  • Divergent mechanisms mean each acts as a partial specificity control for the other.
  • Overlapping behavioural readouts still require separate task designs to interpret.
  • Neither compound should be assumed to share the other’s time course.
  • Our Semax research guide and Selank research guide cover each compound individually.

Handling, reconstitution, and quality verification

Handling is one area where the Semax vs Selank distinction disappears: both are short lyophilized peptides with the same practical requirements.

  • Store the sealed lyophilized vial refrigerated, or frozen long-term, protected from light.
  • Bring the vial to room temperature before opening to avoid condensation on the cake.
  • Reconstitute with bacteriostatic or sterile water down the vial wall, never onto the powder.
  • Swirl gently; vortexing shears peptide chains and promotes aggregation.
  • Refrigerate the reconstituted solution and use within the window your protocol validates.
  • Aliquot once and thaw each aliquot once to avoid repeated freeze-thaw cycles.
  • Record lot, reconstitution date, diluent and concentration for traceability.

Both compounds are supplied at greater than 99% HPLC-verified purity, and COA validity can be confirmed independently at freedomdiagnosticstesting.com using the Accession Number, Client ID or Search Code shown in the product images. For what those documents establish, see our guide to peptide purity, HPLC and mass spectrometry.

Considerations for experimental design

Most of the variables below apply to both compounds, but the first two are where a Semax vs Selank design most often goes wrong.

  • Match the assay to the pathway: neurotrophic and GABAergic endpoints are not substitutes.
  • Immune status: a controlled variable in any Selank model, given the tuftsin lineage.
  • Solution age: treat time-since-reconstitution as a controlled variable.
  • Timescale: transcript-level changes and behavioural changes resolve on different schedules.
  • Vehicle controls: essential where behavioural readouts are sensitive to handling stress.
  • Documentation: lot-level COA references make a result reproducible elsewhere.

Treated carefully, the Semax vs Selank pairing is a useful piece of experimental architecture: two compounds identical in most of the ways that usually confound a comparison, and different in precisely the way being tested.

Frequently asked questions

What is the difference between Semax vs Selank?

They share a design but not a lineage. Semax is a heptapeptide built on the ACTH(4-7) melanocortin fragment and is studied for BDNF, NGF and TrkB neurotrophic signalling, while Selank is a heptapeptide built on the immunopeptide tuftsin and is studied for GABAergic, enkephalinergic and neuroimmune endpoints.

Why do both peptides end in Pro-Gly-Pro?

The C-terminal Pro-Gly-Pro tripeptide is a stabilising modification that confers strong resistance to enzymatic degradation. Without it, both parent fragments would be cleaved too quickly to produce a measurable signal in most research models, so the same solution was applied to two different active sequences.

Which peptide is studied for cognition and which for anxiety?

Semax dominates the learning, memory and neuroprotection literature, reflecting its neurotrophic and monoaminergic activity. Selank appears mainly in anxiety-related behavioural paradigms and GABAergic gene-expression work. The Semax vs Selank split here is one of research emphasis in published models, not a statement about effects in people.

Can Semax and Selank be studied together?

They are often examined as a pair because they are matched for length, chemistry and handling while diverging in mechanism, which makes each a partial specificity control for the other. Combined-arm designs still need single-compound arms if any effect is to be attributed to one peptide.

Are Semax and Selank approved for human use?

No. Both compounds supplied by NeuroPept Labs are sold strictly for in vitro and laboratory research and are not approved, intended or supplied for human or veterinary consumption. They are not drug products and nothing in this article should be read as medical advice or as a recommendation for use in people.

How should these peptides be stored and reconstituted?

Keep the sealed lyophilized vial refrigerated or frozen and protected from light, then bring it to room temperature before opening. Reconstitute with bacteriostatic or sterile water down the vial wall, swirl rather than shake, refrigerate the resulting solution, and aliquot to avoid repeated freeze-thaw cycles.

Research-use-only disclaimer: All products referenced are sold for laboratory and research use only. They are not intended to diagnose, treat, cure, or prevent any disease, and are not for human or veterinary consumption. Researchers working through a Semax vs Selank comparison can start with the Semax and Selank research guides, or review specifications and batch documentation across the current NeuroPept Labs research catalog.

Semax: Nootropic & Neuroprotective Peptide Research

Research-only note: This article is for educational purposes and discusses a compound intended strictly for in vitro and laboratory research. The information below is not medical advice, and the products referenced are not for human consumption.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, studied extensively as a neuroprotective and nootropic research compound. Unlike the parent hormone, it lacks corticotropic (stress-hormone) activity, so in research models it influences neurotrophic and monoaminergic pathways without activating the cortisol axis — the property that makes it a focused tool for cognition and neuroprotection research.

Key takeaways

  • What it is: a synthetic heptapeptide analog of the ACTH(4-10) fragment.
  • No corticotropic effect: influences the brain without activating the cortisol/stress axis.
  • Neurotrophic: studied for increasing BDNF and NGF expression.
  • Monoaminergic: modulates dopamine and serotonin signaling in models.
  • Stability: a Pro-Gly-Pro terminal extension resists enzymatic degradation.
  • Format: supplied as a lyophilized powder with batch-specific third-party analytics.

What is Semax?

Semax is a short synthetic peptide built from the 4-10 sequence of ACTH with an added C-terminal Pro-Gly-Pro tripeptide. That structure is deliberate: the ACTH(4-10) core carries the neurotropic activity, while the appended tripeptide protects the molecule from rapid breakdown. Its defining features are:

  • Heptapeptide structure — a seven-amino-acid sequence, Met-Glu-His-Phe-Pro-Gly-Pro.
  • ACTH(4-10) derived — based on the neuroactive fragment of adrenocorticotropic hormone.
  • Non-hormonal — retains neurotropic activity without the parent hormone’s corticotropic effect.
  • Enzyme-resistant — the Pro-Gly-Pro extension extends its functional stability.

NeuroPept Labs supplies the compound as a research-grade lyophilized peptide verified through independent analytical testing. The published literature is indexed in the PubMed database.

Mechanism of action

Semax’s research interest comes from acting on the brain through several complementary pathways rather than a single receptor. The mechanisms most often described in the literature are:

  • Neurotrophic signaling — increasing expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which support neuron survival and plasticity.
  • Monoaminergic modulation — influencing dopamine and serotonin systems associated with attention and mood.
  • Enkephalin protection — inhibiting enzymes that degrade endogenous regulatory peptides, prolonging their activity.
  • Neuroprotection — antioxidant and anti-apoptotic effects studied in models of neural stress.

The combination of raising neurotrophic factors while modulating monoamine systems is what underlies the compound’s dual reputation as both a neuroprotective and a nootropic research tool.

Why the absence of corticotropic activity matters

A central point in Semax research is that it is derived from ACTH but does not act like it hormonally. Full ACTH stimulates the adrenal glands to release cortisol; the 4-10 fragment used here carries the neural activity without that endocrine effect. For researchers this separation is valuable:

  • Cleaner interpretation — neural effects are not confounded by a cortisol response.
  • No HPA activation — the hypothalamic-pituitary-adrenal stress axis is not engaged.
  • Focused tool — it isolates neurotrophic and monoaminergic signaling for study.

This is why Semax is described as a neuropeptide research tool rather than a hormone: it borrows a hormonal sequence but behaves in the nervous system, not the endocrine system.

Research applications

Current laboratory and preclinical investigation involving Semax spans several neuroscience domains. The following reflect documented research directions, not therapeutic claims:

  • Cognition and memory — studying learning, memory consolidation, and attention in models.
  • Neuroprotection — examining neuronal survival under ischemic or oxidative stress.
  • BDNF and plasticity — mapping neurotrophic signaling and synaptic plasticity.
  • Attention and focus — investigating monoaminergic contributions to attentional performance.
  • Mood-related signaling — assessing serotonergic and dopaminergic modulation.

The endpoints researchers commonly track in these models make the effects measurable:

  • BDNF and NGF expression — neurotrophic-factor levels as a core molecular readout.
  • Cognitive and behavioral measures — learning and memory-task performance in models.
  • Neuronal survival — cell viability under ischemic or oxidative stress.
  • Monoamine dynamics — dopamine and serotonin levels tied to attention and mood.

Across these areas, the peptide is valued for influencing multiple neural pathways at once while leaving the endocrine axis untouched — a profile that makes it a versatile probe for brain research. The neuroprotection literature is indexed in the PubMed database.

Semax and the broader neuropeptide landscape

Semax is often studied alongside other regulatory neuropeptides, because comparing them clarifies how different sequences shape brain signaling. Two useful reference points are:

  • Selank — a tuftsin-derived heptapeptide studied mainly for anxiolytic effects, frequently compared with Semax as a complementary nootropic tool.
  • Endogenous neuropeptides — molecules such as oxytocin illustrate how short peptides can exert broad, receptor-specific effects in the brain.

For a related example of neuropeptide signaling, see our research overview of oxytocin mechanisms. Researchers often pair Semax and Selank in study designs to contrast cognitive and anxiolytic profiles.

Delivery and stability in research

A practical reason for the compound’s popularity as a research tool is its stability, which stems from the Pro-Gly-Pro extension that protects it from peptidase degradation. This stability shapes how it is studied:

  • Intranasal models — much research uses intranasal delivery, which allows the peptide to reach the central nervous system relatively directly in animal models.
  • Metabolic resistance — the terminal tripeptide slows enzymatic breakdown, extending the functional window.
  • Rapid central action — studies report a relatively fast onset of central effects in models.
  • Reproducible exposure — predictable stability supports consistent experimental exposure across runs.

These properties are part of why such a short peptide can be studied as a practical central-nervous-system research tool rather than a fragile laboratory curiosity.

Semax vs Selank at a glance

Because the two are so often studied together, a direct comparison clarifies their distinct profiles:

Feature Semax Selank
Origin sequence ACTH(4-10) Tuftsin
Primary emphasis Cognition, neuroprotection Anxiolytic, calm
Key signaling BDNF/NGF, monoamines GABA/serotonin, neuroimmune
Shared trait Heptapeptide, Pro-Gly-Pro stabilized, non-sedating research tool

The two are complementary rather than interchangeable: one leans toward cognitive and protective signaling, the other toward calming and neuroimmune effects, which is why research designs frequently include both. Studying them side by side also helps researchers separate general “short peptide reaches the brain” effects from the specific contributions of each sequence, since the shared structural backbone lets many other variables be held constant across the comparison.

Handling, reconstitution, and quality verification

Semax is supplied as a lyophilized powder, and its integrity affects the validity of neuroscience models:

  • Storage — keep the lyophilized vial cold and protected from light until use.
  • Reconstitution — add diluent slowly down the vial wall and swirl gently rather than shaking.
  • Concentration records — note exact concentrations so signaling models are accurate.
  • Documentation — confirm a batch-specific certificate of analysis (COA).

Every NeuroPept Labs batch is synthesized under controlled conditions and accompanied by a COA, verifiable at freedomdiagnosticstesting.com using the codes in the product images. For the analytics behind those documents, see our research-grade quality guide.

Considerations for experimental design

Studying a multi-pathway neuropeptide requires design that can separate its several actions:

  • Defined endpoints — choose specific markers such as BDNF expression or a behavioral cognition measure.
  • Pathway controls — account for neurotrophic versus monoaminergic contributions.
  • Model relevance — select cognition, ischemia, or plasticity models that match the question.
  • Verified material — high-purity peptide ensures observed effects reflect the compound itself.

With those controls, a Semax study can attribute a specific outcome to a defined pathway rather than to the compound’s broad activity in general. This precision matters because a molecule that touches neurotrophic, monoaminergic, and neuroprotective systems at once can easily produce results that look impressive but are hard to interpret. A well-designed study isolates one thread at a time — measuring a neurotrophic factor here, a behavioral endpoint there — so that the broad activity resolves into a set of specific, reproducible findings. That discipline, paired with verified starting material, is what turns a versatile but complex research tool into a source of durable data rather than intriguing but ambiguous observations.

Frequently asked questions

What is Semax used for in research?

In research, Semax is studied as a neuroprotective and nootropic peptide, with a focus on BDNF and NGF signaling, monoaminergic modulation, cognition, and neuroprotection. It is used in neuroscience models and is for in vitro and laboratory research only.

Does Semax affect cortisol?

No. Although Semax is derived from the ACTH(4-10) fragment, it lacks the corticotropic activity of full ACTH, so in research models it influences neural pathways without activating the cortisol/stress axis.

How does Semax work?

Semax is studied for increasing neurotrophic factors such as BDNF and NGF, modulating dopamine and serotonin systems, and protecting endogenous regulatory peptides from degradation, together producing neuroprotective and nootropic effects in models.

What is the difference between Semax and Selank?

Both are synthetic heptapeptides studied as nootropics, but Semax is derived from ACTH(4-10) and emphasized for cognition and neuroprotection, while Selank is derived from tuftsin and emphasized for anxiolytic effects. They are often compared as complementary tools.

What form does research-grade Semax come in?

It is supplied as a lyophilized (freeze-dried) peptide powder that is reconstituted before laboratory use and stored under refrigeration, accompanied by a batch-specific certificate of analysis from an independent laboratory.

Is Semax approved for human use?

No. Semax offered for research is intended strictly for in vitro and laboratory investigation and is not approved for human consumption or clinical use. All information here is educational and not medical advice.

Research-use-only disclaimer: All products referenced are sold for laboratory and research use only. They are not intended to diagnose, treat, cure, or prevent any disease, and are not for human or veterinary consumption. Explore the current NeuroPept Labs research catalog, supplied with third-party verified analytics.

SIGN UP TO OUR NEWSLETTER AND SAVE 10% OFF FOR YOUR NEXT PURCHASE

Let's connect! Access Research-Grade Peptide Insights

Join our research newsletter to receive technical updates, documentation guides, and educational content on synthetic peptides and laboratory standards.
All materials are provided for Research Use Only.